Cargando…

Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis, Non-Obstructive Azoospermia

Male infertility is a major health problem affecting about 8–12% of couples worldwide. Spermatogenesis starts in the early fetus and completes after puberty, passing through different stages. Male infertility can result from primary or congenital, acquired, or idiopathic causes. The absence of sperm...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelaal, Nesma E., Tanga, Bereket Molla, Abdelgawad, Mai, Allam, Sahar, Fathi, Mostafa, Saadeldin, Islam M., Bang, Seonggyu, Cho, Jongki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304133/
https://www.ncbi.nlm.nih.gov/pubmed/34359947
http://dx.doi.org/10.3390/cells10071779
_version_ 1783727260060090368
author Abdelaal, Nesma E.
Tanga, Bereket Molla
Abdelgawad, Mai
Allam, Sahar
Fathi, Mostafa
Saadeldin, Islam M.
Bang, Seonggyu
Cho, Jongki
author_facet Abdelaal, Nesma E.
Tanga, Bereket Molla
Abdelgawad, Mai
Allam, Sahar
Fathi, Mostafa
Saadeldin, Islam M.
Bang, Seonggyu
Cho, Jongki
author_sort Abdelaal, Nesma E.
collection PubMed
description Male infertility is a major health problem affecting about 8–12% of couples worldwide. Spermatogenesis starts in the early fetus and completes after puberty, passing through different stages. Male infertility can result from primary or congenital, acquired, or idiopathic causes. The absence of sperm in semen, or azoospermia, results from non-obstructive causes (pretesticular and testicular), and post-testicular obstructive causes. Several medications such as antihypertensive drugs, antidepressants, chemotherapy, and radiotherapy could lead to impaired spermatogenesis and lead to a non-obstructive azoospermia. Spermatogonial stem cells (SSCs) are the basis for spermatogenesis and fertility in men. SSCs are characterized by their capacity to maintain the self-renewal process and differentiation into spermatozoa throughout the male reproductive life and transmit genetic information to the next generation. SSCs originate from gonocytes in the postnatal testis, which originate from long-lived primordial germ cells during embryonic development. The treatment of infertility in males has a poor prognosis. However, SSCs are viewed as a promising alternative for the regeneration of the impaired or damaged spermatogenesis. SSC transplantation is a promising technique for male infertility treatment and restoration of spermatogenesis in the case of degenerative diseases such as cancer, radiotherapy, and chemotherapy. The process involves isolation of SSCs and cryopreservation from a testicular biopsy before starting cancer treatment, followed by intra-testicular stem cell transplantation. In general, treatment for male infertility, even with SSC transplantation, still has several obstacles. The efficiency of cryopreservation, exclusion of malignant cells contamination in cancer patients, and socio-cultural attitudes remain major challenges to the wider application of SSCs as alternatives. Furthermore, there are limitations in experience and knowledge regarding cryopreservation of SSCs. However, the level of infrastructure or availability of regulatory approval to process and preserve testicular tissue makes them tangible and accurate therapy options for male infertility caused by non-obstructive azoospermia, though in their infancy, at least to date.
format Online
Article
Text
id pubmed-8304133
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83041332021-07-25 Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis, Non-Obstructive Azoospermia Abdelaal, Nesma E. Tanga, Bereket Molla Abdelgawad, Mai Allam, Sahar Fathi, Mostafa Saadeldin, Islam M. Bang, Seonggyu Cho, Jongki Cells Review Male infertility is a major health problem affecting about 8–12% of couples worldwide. Spermatogenesis starts in the early fetus and completes after puberty, passing through different stages. Male infertility can result from primary or congenital, acquired, or idiopathic causes. The absence of sperm in semen, or azoospermia, results from non-obstructive causes (pretesticular and testicular), and post-testicular obstructive causes. Several medications such as antihypertensive drugs, antidepressants, chemotherapy, and radiotherapy could lead to impaired spermatogenesis and lead to a non-obstructive azoospermia. Spermatogonial stem cells (SSCs) are the basis for spermatogenesis and fertility in men. SSCs are characterized by their capacity to maintain the self-renewal process and differentiation into spermatozoa throughout the male reproductive life and transmit genetic information to the next generation. SSCs originate from gonocytes in the postnatal testis, which originate from long-lived primordial germ cells during embryonic development. The treatment of infertility in males has a poor prognosis. However, SSCs are viewed as a promising alternative for the regeneration of the impaired or damaged spermatogenesis. SSC transplantation is a promising technique for male infertility treatment and restoration of spermatogenesis in the case of degenerative diseases such as cancer, radiotherapy, and chemotherapy. The process involves isolation of SSCs and cryopreservation from a testicular biopsy before starting cancer treatment, followed by intra-testicular stem cell transplantation. In general, treatment for male infertility, even with SSC transplantation, still has several obstacles. The efficiency of cryopreservation, exclusion of malignant cells contamination in cancer patients, and socio-cultural attitudes remain major challenges to the wider application of SSCs as alternatives. Furthermore, there are limitations in experience and knowledge regarding cryopreservation of SSCs. However, the level of infrastructure or availability of regulatory approval to process and preserve testicular tissue makes them tangible and accurate therapy options for male infertility caused by non-obstructive azoospermia, though in their infancy, at least to date. MDPI 2021-07-14 /pmc/articles/PMC8304133/ /pubmed/34359947 http://dx.doi.org/10.3390/cells10071779 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Abdelaal, Nesma E.
Tanga, Bereket Molla
Abdelgawad, Mai
Allam, Sahar
Fathi, Mostafa
Saadeldin, Islam M.
Bang, Seonggyu
Cho, Jongki
Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis, Non-Obstructive Azoospermia
title Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis, Non-Obstructive Azoospermia
title_full Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis, Non-Obstructive Azoospermia
title_fullStr Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis, Non-Obstructive Azoospermia
title_full_unstemmed Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis, Non-Obstructive Azoospermia
title_short Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis, Non-Obstructive Azoospermia
title_sort cellular therapy via spermatogonial stem cells for treating impaired spermatogenesis, non-obstructive azoospermia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304133/
https://www.ncbi.nlm.nih.gov/pubmed/34359947
http://dx.doi.org/10.3390/cells10071779
work_keys_str_mv AT abdelaalnesmae cellulartherapyviaspermatogonialstemcellsfortreatingimpairedspermatogenesisnonobstructiveazoospermia
AT tangabereketmolla cellulartherapyviaspermatogonialstemcellsfortreatingimpairedspermatogenesisnonobstructiveazoospermia
AT abdelgawadmai cellulartherapyviaspermatogonialstemcellsfortreatingimpairedspermatogenesisnonobstructiveazoospermia
AT allamsahar cellulartherapyviaspermatogonialstemcellsfortreatingimpairedspermatogenesisnonobstructiveazoospermia
AT fathimostafa cellulartherapyviaspermatogonialstemcellsfortreatingimpairedspermatogenesisnonobstructiveazoospermia
AT saadeldinislamm cellulartherapyviaspermatogonialstemcellsfortreatingimpairedspermatogenesisnonobstructiveazoospermia
AT bangseonggyu cellulartherapyviaspermatogonialstemcellsfortreatingimpairedspermatogenesisnonobstructiveazoospermia
AT chojongki cellulartherapyviaspermatogonialstemcellsfortreatingimpairedspermatogenesisnonobstructiveazoospermia